Proton-Pump Inhibitor Therapy Induces Acid-Related Symptoms in Healthy Volunteers After Withdrawal of Therapy

Gastroenterology

Volumn 137, Issue 1, 2009, Pages

  Reimer, Christina ^a   Søndergaard, Bo ^a   Hilsted, Linda ^b   Bytzer, Peter ^a  

^a Mental Health Services CPH   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CHROMOGRANIN A; ESOMEPRAZOLE; GASTRIN;

ACID REGURGITATION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; LONG TERM CARE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REBOUND ACID HYPERSECRETION; SCORING SYSTEM;

EID: 67649222366     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.03.058     Document Type: Article

References (39)

1. Danish Medicines Agency. Medicinal product statistics in Denmark 2007 (2008), Danish Medicines Agency, Copenhagen
2. Lassen A., Hallas J., and Schaffalitzky de Muckadell O.B. Use of anti-secretory medication: a population-based cohort study. Aliment Pharmacol Ther 20 (2004) 577-583
3. National Institute for Clinical Excellence (NICE). NICE clinical guideline 17. Dyspepsia-management of dyspepsia in adults in primary care (2004), NICE, London
4. Talley N.J., and Vakil N. Guidelines for the management of dyspepsia. Am J Gastroenterol 100 (2005) 2324-2337
5. National Institute for Clinical Excellence (NICE). 2000/022 NICE issues guidance on proton pump inhibitors for dyspepsia (2000) London, UK
6. Raghunath A.S., O'Morain C., and McLoughlin R.C. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 22 Suppl 1 (2005) 55-63
7. Van Soest E.M., Siersema P.D., Dieleman J.P., et al. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 24 (2006) 377-385
8. Martin R.M., Lim A.G., Kerry S.M., et al. Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol Ther 12 (1998) 797-805
9. Pollock K., and Grime J. The cost and cost-effectiveness of PPIs-GP perspectives and responses to a prescribing dilemma and their implications for the development of patient-centred healthcare. Eur J Gen Pract 9 (2003) 126-133
10. Gillen D., Wirz A.A., Ardill J.E., et al. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 116 (1999) 239-247
11. Waldum H.L., Arnestad J.S., Brenna E., et al. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 39 (1996) 649-653
12. Hunfeld N.G., Geus W.P., and Kuipers E.J. Systematic review: Rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther 25 (2007) 39-46
13. US Food and Drug Administration. Rebound of gastric acid secretion (2000). http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3650b1a_11.pdf Accessed March 17, 2009
14. Laine L., Ahnen D., McClain C., et al. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 14 (2000) 651-668
15. Sanduleanu S., Stridsberg M., Jonkers D., et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther 13 (1999) 145-153
16. Waldum H.L., Sandvik A.K., Syversen U., et al. The enterochromaffin-like (ECL) cell. Physiological and pathophysiological role. Acta Oncol 32 (1993) 141-147
17. Revicki D.A., Wood M., Wiklund I., et al. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res 7 (1998) 75-83
18. Dimenas E., Glise H., Hallerback B., et al. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 30 (1995) 1046-1052
19. Kulich K.R., Madisch A., Pacini F., et al. Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study. Health Qual Life Outcomes 6 (2008) 12
20. Ware Jr. J.E. Physical and mental health summary scales: a user's manual (2008), The Health Institute, New England Medical Center, Boston
21. Borglum T., Rehfeld J.F., Drivsholm L.B., et al. Processing-independent quantitation of chromogranin a in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas. Clin Chem 53 (2007) 438-446
22. Hilsted L., and Rehfeld J.F. Measurement of precursors for alpha-amidated hormones by radioimmunoassay of glycine-extended peptides after trypsin-carboxypeptidase B cleavage. Anal Biochem 152 (1986) 119-126
23. Lindberg G., and Vieri J. Dyspepsia after withdrawal of omeprazole in healthy volunteers. Gastroenterology 124 Suppl 1 (2003) A-225
24. Sharma B.K., Walt R.P., Pounder R.E., et al. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut 25 (1984) 957-964
25. Bell N., Karol M.D., Sachs G., et al. Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. Aliment Pharmacol Ther 15 (2001) 105-113
26. Sharma B., Axelson M., Pounder R.P., et al. Acid secretory capacity and plasma gastrin concentration after administration of omeprazole to normal subjects. Aliment Pharmacol Ther 1 (1987) 67-76
27. Niklasson A., Lindström L., Simren M., et al. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: clinical importance of acid-rebound. Gastroenterology 134 Suppl 1 (2008)
28. Gillen D., Wirz A.A., Neithercut W.D., et al. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 44 (1999) 468-475
29. Hunfeld N.G., Geus W.P., and Kuipers E.J. Systematic review: Rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther 25 (2007) 39-46
30. Sanduleanu S., De Bruine A., Stridsberg M., et al. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 31 (2001) 802-811
31. D'Adda T., Pilato F.P., Lazzaroni M., et al. Ultrastructural morphometry of gastric endocrine cells before and after omeprazole. A study in the oxyntic mucosa of duodenal ulcer patients. Gastroenterology 100 (1991) 1563-1570
32. Smith A.D., Gillen D., Cochran K.M., et al. Dyspepsia on withdrawal of ranitidine in previously asymptomatic volunteers. Am J Gastroenterol 94 (1999) 1209-1213
33. Qvigstad G., Arnestad J.S., Brenna E., et al. Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients. Scand J Gastroenterol 33 (1998) 1244-1248
34. Bjornsson E., Abrahamsson H., Simren M., et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 24 (2006) 945-954
35. Raghunath A.S., Hungin A.P., Mason J., et al. Helicobacter pylori eradication in long-term proton pump inhibitor users in primary care: a randomized controlled trial. Aliment Pharmacol Ther 25 (2007) 585-592
36. Wiklund I., Carlsson J., and Vakil N. Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community. Am J Gastroenterol 101 (2006) 18-28
37. Wiklund I.K., Junghard O., Grace E., et al. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl (1998) 41-49
38. Naunton M., Peterson G.M., and Bleasel M.D. Overuse of proton pump inhibitors. J Clin Pharm Ther 25 (2000) 333-340
39. Fossmark R., Johnsen G., Johanessen E., et al. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 21 (2005) 149-154